Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
- 1 December 2007
- journal article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 5 (12), 2429-2436
- https://doi.org/10.1111/j.1538-7836.2007.02775.x
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metaboliteJournal of Thrombosis and Haemostasis, 2007
- INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450Drug Metabolism and Disposition, 2006
- Dependence of Platelet Thrombus Stability on Sustained Glycoprotein IIb/IIIa Activation Through Adenosine 5′-Diphosphate Receptor Stimulation and Cyclic Calcium SignalingJournal of the American College of Cardiology, 2006
- Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humansPlatelets, 2006
- Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humansPlatelets, 2006
- Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis: Results of the CREST StudyJournal of the American College of Cardiology, 2005
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterizationThe American Journal of Cardiology, 2004
- Clopidogrel for Coronary StentingCirculation, 2003
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002